ACTRN12615000645550招募中2 期
Effect of lycosomal formulation of lycopene and resveratrol chaperoned phosphatidylcholine on viral load and liver function in patients with hepatitis c
ycotec Ltd, Cambridge, UK0 个研究点目标入组 120 人开始时间: 2015年6月23日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •1.Consented males or females 18-65 years of age and testing positive for any HCV genotype on the standard interferon therapy.
- •2.Newly diagnosed cases of Hepatitis C as well as patients with chronic Hepatitis C patients positive in quantitative and qualitative PCR with concomitant increase of liver-specific enzymes in serum (>2 folds over control level).
- •3.Stable clinical conditions not requiring emergency care
排除标准
- •1.Clinically significant infection, other than HCV, defined as any acute viral, bacterial, or fungal infection, which requires specific therapy.
- •2.Co-infections with Hepatitis B virus and Human immunodeficiency virus (HIV).
- •3.Received any investigational drug agent(s) within 28-days of entry into study.
- •4.Any known pre-existing medical condition that could interfere with the subject's participation in the protocol, including serious psychiatric disorders, CNS trauma or active seizure disorders requiring medication, poorly controlled diabetes mellitus, significant cardiovascular dysfunction within the past 6 months (e.g., angina, congestive heart failure, recent myocardial infarction, severe hypotension, or significant arrhythmia).
- •5.Subjects with ECG showing clinically significant abnormalities.
- •6.Need for frequent blood transfusions.
- •7.Recent History of bleeding or bleeding disorders requiring the restriction in use of anticoagulants during study treatments.
- •8.Active immunologically mediated disease (e.g., inflammatory bowel disease [Crohn's disease, ulcerative colitis], rheumatoid arthritis, idiopathic thrombocytopenia purpura, systemic lupus erythematosus, autoimmune or inherited hemolytic anemia, scleroderma, severe psoriasis).
- •9.Any medical condition, other than HCV, requiring, or likely to require during the course of the study, chronic systemic administration of steroids or other immune-regulatory medications.
- •10.Substance abuse, such as alcohol (~80 gm/day), IV drugs, and inhaled drugs (If the subject has a history of substance abuse, to be considered for inclusion into the protocol, the subject must have abstained from using the abused substance for at least 2 months.
- •11.Any cancer requiring systemic chemotherapy.
- •12.Any other condition that, in the opinion of the principal investigators or treating physicians, would make the subject unsuitable for enrollment, or could interfere with the subject participating in and completing the expanded access protocol.
研究者
相似试验
招募中
不适用
Effect of lycosome-formulated dark chocolate on serum lipid profile and parameters of cardiovascular healthhypertensionhyperlipidemiaACTRN12613000966796ycotec Ltd, United Kingdom80
已完成
1 期
Checking the effect of lycopene supplement when consumed orally after non-surgical gum therapy.CTRI/2018/02/011759none30
尚未招募
3 期
Evaluation of the systemic use of Lycopene supplementation on non-surgical periodontal treatmentchronic periodontitis.Chronic periodontitisK05.3IRCT20230830059303N1Yazd University of Medical Sciences42
招募中
2 期
Effect of lycopene chaperoned with phosphatidylcholine on progression and outcomes of nonalcoholic steatohepatitis.ACTRN12615000386538ycotec Ltd, Cambridge, UK80
已完成
3 期
The Effect of Lycopene and FruHis supplementation on serum levels of PSA in BPH patientsIRCT20190522043669N1Tehran University of Medical Sciences80